Noble Financial Weighs in on MariMed FY2026 Earnings

MariMed Inc. (OTCMKTS:MRMD) – Equities research analysts at Noble Financial issued their FY2026 EPS estimates for MariMed in a report released on Monday, March 16th. Noble Financial analyst J. Gomes expects that the company will post earnings of ($0.05) per share for the year.

Separately, Zacks Research raised shares of MariMed from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, MariMed has an average rating of “Moderate Buy”.

MariMed Trading Down 3.2%

Shares of MRMD opened at $0.08 on Wednesday. The company’s fifty day simple moving average is $0.09 and its 200-day simple moving average is $0.11. The company has a market cap of $29.83 million, a P/E ratio of -2.50 and a beta of 1.11. The company has a current ratio of 1.00, a quick ratio of 0.38 and a debt-to-equity ratio of 1.44. MariMed has a twelve month low of $0.07 and a twelve month high of $0.23.

MariMed Company Profile

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.